What Viagra (sildenafil) trial did Pfizer run first, and what was the goal?
Pfizer’s sildenafil (Viagra) was developed through clinical testing designed to assess safety and determine whether it worked for erectile dysfunction. The early studies were meant to show that the drug could improve erections in men with erectile dysfunction and that the overall risk profile was acceptable for later, larger trials.
What did early sildenafil trials measure?
Across erectile dysfunction clinical development, Pfizer’s trials focused on endpoints commonly used in that condition, such as whether erections were sufficient for sex (as reported by patients), and whether treatment produced measurable improvements versus placebo, while monitoring adverse effects.
When did Viagra’s clinical testing happen?
Sildenafil’s development and clinical testing occurred over the late 1990s, leading into regulatory review and approval in the early 2000s. (Detailed trial-by-trial dates and designs depend on the specific study identifier, dose, and phase.)
Were sildenafil trials placebo-controlled, and who participated?
Erectile dysfunction trials for sildenafil were typically randomized and compared sildenafil to placebo, enrolling men diagnosed with erectile dysfunction. Inclusion criteria and specific demographics depended on the protocol and the trial phase.
What happened after Pfizer’s trials—was the drug approved?
After clinical testing supported efficacy and safety, sildenafil was submitted for regulatory approval and eventually launched as Viagra for erectile dysfunction. The exact approval pathway and labeling (including contraindications and warnings) were shaped by the combined clinical dataset.
Looking for the exact Pfizer trial (NCT number, phase, and publication)?
If you want, share any extra detail you have (for example, the study year, whether you mean Phase 1, Phase 2, or Phase 3, or a paper title). Then I can point you to the specific Pfizer sildenafil trial records and the corresponding results/patient populations.